臨床整形外科59巻8号

2024年08月発行

特集 脊損患者への投与が始まった脊髄再生医療—脊髄損傷患者に希望が見えるか

顆粒球コロニー刺激因子(G-CSF)を用いた急性脊髄損傷の治療

著者： 國府田正雄¹⁴ 古矢丈雄²⁴ 花岡英紀³⁴ 牧聡²⁴ 山崎正志¹⁴

所属機関： ¹筑波大学医学医療系整形外科 ²千葉大学大学院医学研究院整形外科 ³千葉大学附属病院臨床試験部 ⁴G-SPIRIT研究グループ

ページ範囲：P.1007 - P.1011

脊髄損傷に対する顆粒球コロニー刺激因子(G-CSF)の有効性を明らかにするための検証的試験を医師主導治験にて実施した．主要評価項目ではG-CSF投与群とプラセボ群の間に有意な差はなかったが，サブ解析の結果高齢者においては麻痺回復促進効果が示唆された．

参考文献

1) Yang B, Zhang F, Cheng F, et al. Strategies and prospects of effective neural circuits reconstruction after spinal cord injury. Cell Death Dis 2020;11(6):439. doi:10.1038/s41419-020-2620-z.

2) Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury:results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322(20):1405-11. doi:10.1056/NEJM199005173222001.

3) Hejrati N, Fehlings MG. A review of emerging neuroprotective and neuroregenerative therapies in traumatic spinal cord injury. Curr Opin Pharmacol 2021;60:331-40. doi:10.1016/j.coph.2021.08.009.

4) Hurlbert RJ, Hadley MN, Walters BC, et al. Pharmacological therapy for acute spinal cord injury. Neurosurgery 2013;72:93-105.

5) Nicola NA, Metcalf D, Matsumoto M, et al. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 1983;258(14):9017-23.

6) Roberts AW. G-CSF:a key regulator of neutrophil production, but that's no all!. Growth Factors 2005;23(1):33-41.

7) Koda M, Nishio Y, Kamada T, et al. Granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into injured spinal cord and promotes functional recovery after compression-induced spinal cord injury in mice. Brain Res 2007;1149(1):223-31.

8) 國府田正雄，西尾豊，門田領・他．急性脊髄損傷に対する顆粒球コロニー刺激因子(G-CSF)を用いた神経保護療法．日整会誌2012；86(7)：495-8．

9) Takahashi H, Yamazaki M, Okawa A, et al. Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury:a phase I/IIa clinical trial. Eur Spine J2012;21(12):2580-7.

10) Inada T, Takahashi H, Yamazaki M, et al. Multicenter prospective nonrandomized controlled clinical trial to prove neurotherapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury:analyses of follow-up cases after at least one year. Spine (Phila Pa 1976) 2014;39(3):213-9.

11) Koda M, Hanaoka H, Sato T, et al. Study protocol for the G-SPIRIT trial:a randomised, placebo-controlled, double-blinded phase III trial of granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury. BMJ Open 2018;8(5):e019083. doi:10.1136/bmjopen-2017-019083.

12) Koda M, Hanaoka H, Fujii Y, et al. Randomized trial of granulocyte colony-stimulating factor for spinal cord injury. Brain 2021;144(3):789-99. doi:10.1093/brain/awaa466.

13) Hooshmand MJ, Galvan MD, Partida E, et al. Characterization of recovery, repair, and inflammatory processes following contusion spinal cord injury in old female rats:is age a limitation? Immun Ageing 2014;11:15. doi:10.1186/1742-4933-11-15.

14) Kamiya K, Furuya T, Hashimoto M, et al. Exploration of spinal cord aging-related proteins using a proteomics approach. J Exp Neurosci 2017;11:1-5. doi:10.1177/1179069517713019.